Search results
Showing results for
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
Methods for the development and validation of computable phenotypes based on biobanks and linked real world data
Deadline - Friday 15 May 2026